Innovative drug out-licensing deal value vs First-in-class drug approvals in China
In 2025, innovative drug out-licensing deal value in China was 130 billion USD; first-in-class drug approvals was 11.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time from 2024 to 2025 . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.
Innovative drug out-licensing deal value
Unit: billion USD · 2 observations
First-in-class drug approvals
Unit: count · 2 observations
Shared periods
Side by side
Only 2 periods are published for both series in China. Comparing anything else would mean comparing different years.
| Period | Innovative drug out-licensing deal value | First-in-class drug approvals |
|---|---|---|
| 2024 | 51.9 billion USD | 48 |
| 2025 | 130 billion USD | 11 |
Provenance
Where these numbers come from
Innovative drug out-licensing deal value
Total monetary value of out-licensing agreements signed for innovative pharmaceutical products.
2 observations in China · source organisations: NHSA
First-in-class drug approvals
Number of approved therapeutic drugs featuring a novel biological mechanism of action.
4 observations in China · source organisations: NMPA, NHSA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring